BRAF and neoplasm: As a third case report, we present patient CRC-0042 (stage II) who had the following mutations detectable by sequencing of the original tumor: BRAF (N581I at 28.7% VAF), NRAS (G12V at 41.9%), and PIK3CA (E545K at 57.7%).